The use of angiotensin-converting enzyme inhibitors in patients undergoing coronary artery bypass graft surgery

Vascul Pharmacol. 2005 Feb;42(3):119-23. doi: 10.1016/j.vph.2005.01.012.

Abstract

Angiotensin-converting enzyme inhibitors have been shown to prolong survival, decrease infarct size, and improve ventricular function in patients who have congestive heart failure, and in those who have sustained a myocardial infarction. This review will summarize the evidence to show that angiotensin-converting enzyme inhibitors can also benefit patients undergoing coronary artery bypass graft surgery by minimizing perioperative ischemia, and reducing long-term cardiovascular events.

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Coronary Artery Bypass* / methods
  • Coronary Artery Disease / drug therapy*
  • Coronary Artery Disease / enzymology
  • Humans

Substances

  • Angiotensin-Converting Enzyme Inhibitors